

Development Stage

- In vitro data available
- In vivo data available (animal)

Inventors: John Chiorini and Giovanni Pasquale (NIDCR).

Publication: Schmidt M, et al. Identification and characterization of novel adeno-associated virus isolates in ATCC virus stocks. J Virol. 2006 May; 80 (10): 5082–5098. [PMID 16641301]

Intellectual Property: HHS Reference No. E-175–2015/0—US Application No. 62/160,552 filed May 12, 2015.

Related Technologies

- E-097–2015: US 62/143,524.
- E-736–2013: PCT/US14/59825.
- E-142–2011 family: PCT/US12/34268, CA, EP and US.
- E-087–2011 family: PCT/US12/33556, EP and US.
- E-232–2011: US 14/428,929.
- E-194–2010: US 8,808,684.
- E-179–2005: US 8,283,151.
- E-227–2004: US 7,407,801.
- E-329–2003 family: US 8,137,960, US 8,685,722.
- E-105–2003: US 8,927,269.
- E-308–2001: US 7,419,817.
- E-071–2000: US 6,468,524.
- E-127–1998 family: US 6,984,517, AU, CA, EP, and JP.

Licensing Contact: Sally Hu, Ph.D., M.B.A.; 301–435–5606; hus@mail.nih.gov.

Collaborative Research Opportunity: The National Institute of Dental and Craniofacial Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize AAV44–9 vector for gene therapy. For collaboration opportunities, please contact David Bradley, Ph.D. at bradleyda@nidcr.nih.gov.

WNT1-Induced Secreted Protein-1 Knockout Mouse Model

Description of Technology: WNT1-induced secreted protein-1 (WISP1) is expressed at high levels in osteoblasts and their precursors. WISP1 plays an important role in various aspects of bone formation. Scientists at the NIH generated *Wisp1*-deficient (*Wisp1*^{-/-}) mice. Deletion of *Wisp1* resulted in a decrease in bone mineral density, total bone volume, bone thickness, and biomechanical strength. *Wisp1* knockout mouse model can be used to study the molecular mechanisms of bone turnover and patho/physiology of tissues that express WISP1.

Potential Commercial Applications

- To study the molecular mechanisms of bone formation and osteodifferentiation.

- To study the patho/physiology of tissues that express WISP1, including cartilage during osteoarthritis, healing skin, and other soft tissues including lung, pancreas, and heart.

Development Stage: In vivo data available (animal).

Inventors: Marian F. Young, Mitsuaki Ono, Azusa Maeda (all of NIDCR).

Publication: Maeda A, et al. WNT1-induced secreted protein-1 (WISP1), a novel regulator of bone turnover and Wnt signaling. J Bio Chem. 2015 May 29;290(22):14004–18. [PMID 25864198]

Intellectual Property: HHS Reference No. E-234–2015/0—Research Tool. Patent protection is not being pursued for this technology.

Licensing Contact: Sally Hu, Ph.D., M.B.A.; 301–435–5606; hus@mail.nih.gov

Collaborative Research Opportunity: The National Institute of Dental and Craniofacial Research is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize WNT1-Induced Secreted Protein-1 Knockout Mouse Model. For collaboration opportunities, please contact David Bradley, Ph.D. at bradleyda@nidcr.nih.gov.

Dated: July 30, 2015.

Richard U. Rodriguez,

Acting Director, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2015–19082 Filed 8–3–15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****National Institute of Neurological Disorders and Stroke: Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special

Emphasis Panel; Review of U24 Applications for Parkinson's Disease Repositories.

Date: August 11, 2015.

Time: 9:00 a.m. to 1:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Joel A. Saydoff, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive Boulevard, Suite 3205, MSC 9529, Bethesda, MD 20892–9529, 301–435–9223, joel.saydoff@nih.gov.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; Review of U01 Applications for Parkinson's Disease Biomarker Program.

Date: August 12, 2015.

Time: 8:00 a.m. to 12:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852, (Telephone Conference Call).

Contact Person: Joel A. Saydoff, Ph.D., Scientific Review Officer, Scientific Review Branch, Division of Extramural Research, NINDS/NIH/DHHS/Neuroscience Center, 6001 Executive Boulevard, Suite 3205, MSC 9529, Bethesda, MD 20892–9529, 301–435–9223.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: July 29, 2015.

Carolyn Baum,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2015–19032 Filed 8–3–15; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES**National Institutes of Health****Center for Scientific Review: Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which